We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
14 result(s) found, displaying 1 to 10
-
Sep-2025Prescription medicine evaluationActive ingredient: vutrisiran sodium.
-
Australian public assessment report (AusPar)Oxlumo (lumasiran) has been approved for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OXLUMO lumasiran (as sodium) 94.5 mg/0.5 mL injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMVUTTRA, vutrisiran (as sodium) 25 mg / 0.5 mL solution for injection pre-filled syringe.
-
Australian public assessment report (AusPar)Amvuttra (vutrisiran) has been approved for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with polyneuropathy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for GIVLAARI givosiran 189 mg/1mL solution for injection vial.
-
Prescription medicine decision summaryAmvuttra (vutrisiran) was approved for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
-
Australian public assessment report (AusPar)Givlaari (givosiran sodium) has been approved for the treatment of acute hepatic porphyria.
-
Prescription medicine registrationActive ingredients: lumasiran sodium.